Research
Adherence
Higher doses of orforglipron (36-45 mg) are associated with increased treatment discontinuation due to adverse events compared to lower doses and placebo.
Higher doses of orforglipron work better for weight loss but cause more side effects, leading some people to stop taking it. If you struggle with side effects, ask your doctor about a lower dose (24-36 mg) which may be easier to tolerate.
GoodQualifiesHIGH confidence
All doses showed higher rates of total adverse events and treatment discontinuation than placebo, while serious adverse events and specific gastrointestinal symptoms (nausea, vomiting, dyspepsia) were lower than placebo.
Why this rating
Based on RCT data, though discontinuation rates are high.
Source
Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis
Marwan Tantoush et al. · Cureus · 2026
Meta-analysis · 5 studiesCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →